1. Home
  2. DNUT vs MNPR Comparison

DNUT vs MNPR Comparison

Compare DNUT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krispy Kreme Inc.

DNUT

Krispy Kreme Inc.

HOLD

Current Price

$3.53

Market Cap

672.4M

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$96.71

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNUT
MNPR
Founded
1937
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
672.4M
587.4M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
DNUT
MNPR
Price
$3.53
$96.71
Analyst Decision
Hold
Strong Buy
Analyst Count
5
11
Target Price
$4.15
$107.00
AVG Volume (30 Days)
2.9M
144.8K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.99
EPS
N/A
N/A
Revenue
$1,522,616,000.00
N/A
Revenue This Year
$0.55
N/A
Revenue Next Year
$3.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.88
$29.18
52 Week High
$5.73
$105.00

Technical Indicators

Market Signals
Indicator
DNUT
MNPR
Relative Strength Index (RSI) 47.07 83.34
Support Level $3.13 $52.92
Resistance Level $3.66 $103.17
Average True Range (ATR) 0.22 6.06
MACD -0.03 2.84
Stochastic Oscillator 10.34 93.86

Price Performance

Historical Comparison
DNUT
MNPR

About DNUT Krispy Kreme Inc.

Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: